Program

THURSDAY, APRIL 24th, 2014
PRE-MEETING EVENT

13.00-19.00 CINP EDUCATIONAL WORKSHOP: UPDATE ON NEUROPSYCHOPHARMACOLOGY
Brian Leonard (Galway, Ireland) & Gregers Wegener (Aarhus, Denmark) 

FRIDAY, APRIL 25th, 2014

09.00- REGISTRATION OPENS

10.00-10.05 PRESIDENT´S WELCOME

10.05-11.00  OPENING LECTURE
Recent advancements of molecular imaging on monoaminergic neurotransmission systems
Lars Farde (Stockholm, Sweden)

11.00-13.00   SYMPOSIUM

Tobacco smoking in psychiatric patients - a harmful self-medication wíth nicotine? 

Tobacco smoking in major psychiatric disorders: why do our patients smoke as much as they do?'
Leif Lindström (Uppsala, Sweden) 

Future medication in schizophrenia and depression: Role of alpha 7 nicotinic receptor agonists, partial  agonists and positive allosteric modulators.
Torgny H. Svensson (Stockholm, Sweden)

Nicotinic receptor agonists and antagonists in animal models of depression
Jesper T. Andreasen (Copenhagen, Denmark)

Smoking cessation in psychiatric patients. Pharmacological treatment alternatives and outcomes.
Pros and Cons of e-cigarrettes
Karl-Olov Fagerström (Sweden)

13.00-13.45  LUNCH 

13.45-15.15  SCNP YOUNG SCIENTIST SYMPOSIUM

Speakers to be announced (based on competition)

15.15-15.45  COFFEE BREAK

15.45-16.30 SCNP LECTURE
Probiotics: a novel treatment avenue in psychiatric disorders?
John F. Cryan (Cork, Ireland)

16.30-18.00   DEBATE SYMPOSIUM
Antidepressants. Is efficacy a myth?

Elias Eriksson (Gothenburg, Sweden)
David Healy (Bangor, United Kingdom)

18.00-19.30 POSTER SESSION. 

Refreshments

19.30-     SCNP 2014 RECEPTION IN POSTER AND EXHIBITION AREA.
Standing dinner with food and wine 

SATURDAY, APRIL 26th, 2014

09.00-09.45  SCNP LECTURE
DSM5 - facts and fiction
Hans Ågren (Gothenburg, Sweden)

09.45-10.15  COFFEE BREAK

10.15-11.45   SYMPOSIUM
Treatment of alcohol dependence: a current update

Extending Treatment Options in Alcohol Use Disorders: the Nalmefene Data.
Karl Mann (Heidelberg, Germany)

Recent RCTs on Alcohol Dependence – Mixed Effects of Varenicline (partial nicotine receptor agonist) and Org 25935 (glycine uptake inhibitor)
Bo Söderpalm (Gothenburg, Swenden)

The Gut-Brain Axis and Addiction: The Involvement of Gastrointestinal Hormones in the Brain Reward Orchestra.
Jörgen A Engel (Gothenburg, Sweden)

11.45-13.15   SYMPOSIUM 
New treatment options in ADHD

Current evidence for pharmacological treatments in adult ADHD.
Marios Adamou (Wakefield, United Kingdom)

Current evidence for psychological treatments of adult ADHD.
Brynjar Emilsson (Reykjavik, Iceland)

New treatment options in adult ADHD.
Anne Halmoy (Bergen, Norway)

13.15-14.00  LUNCH 

14.00-15.30  SYMPOSIUM
Novel approaches in Schizophrenia

Stratifying schizophrenia: Can we use neurochemical imaging and genetic data to target responders to novel glutamatergic drugs in schizophrenia?
James MacCabe (London, United Kingdom)

Striatal and extrastriatal dopamine D2/3 receptor binding and reward abnormalities in antipsychotic-naïve first-episode patients with schizophrenia: Relation to treatment outcome? 
Birte Glenthøj (Copenhagen, Denmark)

Subgrouping of antipsychotic-naïve first-episode schizophrenia patients based on by the application of unsupervised machine learning approached on cognitive and psychophysiological data
Nikolaj Bak (Copenhagen, Denmark)

15.30-16.00  COFFEE BREAK

16.00-17.30  SYMPOSIUM
New discoveries and potential for drug development?

The Sensodetect® - method as biomarkers and diagnostic support for schizophrenia and adult ADHD in relation to healthy controls.
Eva Baghdassarian (Uppsala, Sweden)

Can new psychiatric genetics findings facilitate drug targets
Ole A. Andreasen (Oslo, Norway)

Metabolomics - can it give a potential link to drug targets?
Matej Orešič (Helsinki, Finland)

17.30             CONCLUSION OF MEETING